Agilon Health price target lowered to $22 from $28 at Benchmark

Benchmark analyst Bill Sutherland lowered the firm’s price target on Agilon Health to $22 from $28 and keeps a Buy rating on the shares. Even after yesterday’s 8% recovery, Agilon has plummeted by about 30% in the week since its Q3 release, triggered by below-trend medical margin, the analyst tells investors. The firm has “modestly brought in” its medical margin assumptions through 2026, but remains above consensus and sees a high growth model with above average visibility supporting a higher valuation, the analyst added.